The biopharmaceutical company Hybrigenics announced on Monday it had received a takeover bid from "a French company listed on Euronext which does not want to be named at this stage of discussions under confidentiality agreement."
This takeover bid would be made through a partial contribution of assets that would consist of a subsidiary of that company whose identity is not known, Hybrigenics said.
The company's board of directors intends to carry out the necessary checks and analyzes to "determine the best conditions under which such an operation could be structured with a view to the possible approval of the shareholders."
However, the board currently considers that "the offer received may be a better alternative, in a friendly way, the settlement planned so far," according to the company statement.
On October 23, Hybrigenics announced the discontinuation of the clinical trial of incalcitol, a vitamin D receptor agonist molecule, its only product in development. Hybrigenics had then proposed that its shareholders dissolve the company. After a first meeting on December 20, when the quorum had not been reached, shareholders had to vote for dissolution at a joint general meeting scheduled for January 15.
-Julien Marion, Agefi-Dow Jones; +33 (0) 1 41 27 47 94; [email protected] ed: VLV
Agefi-Dow Jones The Financial Bulletin